We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | 5,013,886 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
From Jan 2020 to Jan 2025
By Adria Calatayud
GlaxoSmithKline PLC said Tuesday that ViiV Healthcare, the specialist HIV company in which it holds a majority stake, has signed a licensing agreement that gives it exclusive access to Halozyme Therapeutics Inc.'s Enhanze drug-delivery technology.
The collaboration will allow ViiV to develop long-acting medicines for HIV, GlaxoSmithKline said. Under the agreement, ViiV will make an upfront payment of $40 million to Halozyme for am exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million, subject to hitting some development and commercial milestones, GlaxoSmithKline said.
The U.K. pharmaceutical giant said ViiV plans to start the first experiments with the technology by the end of 2021.
ViiV is majority-owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi & Co. as shareholders.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 22, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
